AADI (Aadi Bio) שולי הרווח הגולמי

Aadi Bioscience delegates drug manufacturing and testing to external contractors to maintain flexibility. The primary focus is on the academic environment and the development of targeted mTOR inhibitors, where scientists are incentivized by stock options. The consistent performance of partner laboratories confirms the effectiveness of this model. The current gross margin demonstrates financial stability, with the indicator standing at 87.40.
פילוחי מדדים פיננסיים ומדדי שוק עבור Aadi Bio (AADI)

Gross margin determines production efficiency by measuring the portion of revenue remaining after direct product creation costs. Stable utilization of biotechnological complexes and the absence of downtime in contract drug manufacturing are reflected in the consolidated gross margin trend for Aadi Bioscience (AADI). Analyzing this metric allows investors to assess the asset's operating profitability and determine the company's fair cost of capital.